Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

FGF21-engineered ADSCs promote diabetic wound healing by mitigating ferroptosis and oxidative stress via the SIRT1/NRF2/GPX4 signaling pathway.

Liang Z., Gu Y., Li Y., Wu Z., Xu X., Wei G.

Animal Study on Diabetic Foot, Chronic Wound, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Res Ther (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41257858
PMCID
PMC12628967
DOI
10.1186/s13287-025-04758-9
Citations
8

Abstract (original English)

Background ADSCs and growth factor-based therapies are widely investigated for diabetic wound healing. However, the clinical translation of ADSCs is limited by their biological instability under hyperglycemic conditions, while exogenous growth factors face challenges such as short half-life and high production costs. Here, we propose a novel strategy using FGF21-engineered ADSCs (ADSC FGF21 ), leveraging the dual advantages of stem cell paracrine effects and FGF21's established role in metabolic regulation, to target ferroptosis and oxidative stress, key pathological drivers of delayed wound healing in diabetes. Methods To investigate ferroptosis in diabetic wounds, we quantified iron accumulation, DNA oxidative damage (8-OHdG), and lipid peroxidation (MDA assay) in diabetic wound tissues. In vitro, high glucose (HG) treated HUVEC, a model for endothelial dysfunction, were subjected to 7-AAD staining, BODIPY C11-based lipid peroxidation assays, and transmission electron microscopy (TEM) to assess ferroptosis hallmarks. The therapeutic effects of ADSC FGF21 were evaluated through CCK-8 proliferation assays, scratch wound healing, and Matrigel-based tube formation assays under HG conditions. Mechanistic studies involved flow cytometry for ferroptosis distinction, qPCR/Western blot for SIRT1/NRF2/GPX4, AMPK pathway analysis, and immunofluorescence to track NF-κB p65 nuclear transl

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Oxidative StressFerroptosisWound HealingSirtuin 1HumansNF-E2-Related Factor 2Fibroblast Growth FactorsAnimalsSignal TransductionMice

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research